Revenue rose by 20% annually to Rs 1,284 crore between FY20 and FY22, while net profit dropped by 16% to Rs 76.4 crore. Revenue growth was driven by the acquisition of SGS. This however resulted in a sharp drop in the operating margin before depreciation and amortisation (EBITDA margin) to 11.3% in FY22 from 16.8% in FY20.
Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?
Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defence, Capital Markets, and Metals—are showing remarkable strength.
May 25, 2026